Clinical trial
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple…
NCT00322842 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00322842 |
|---|---|
| Title | Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients |
| Official title | Treatment With AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | AnorMED Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin, Multiple Myeloma |
| Intervention type | Drug |
| Interventions | G-CSF Plus Plerixafor |
| Enrollment | 35 |
| Start date | Sep 1, 2004 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | May 8, 2006 |
| Last update posted | Mar 13, 2014 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: